Abstract
Integrins α1β1 and α2β1 are highly expressed on the microvascular endothelial cells, and blocking of their adhesive properties significantly reduced the VEGF-driven neovascularization ratio and tumor growth in animal models. Hence, inhibitors of the α1β1 and α2β1 integrins, alone or in combination with antagonists of other integrins involved in angiogenesis (eg. αvβ3, αvβ5, and α6β4), may prove benefitial in the control of tumor neovascularization. Viperidae snakes have developed in their venoms an efficient arsenal of integrin receptor antagonists. KTS- (obtustatin, viperistatin, lebestatin) and RTS- (jerdostatin) disintegrins represent viper venom peptides that specifically block the interaction of the α1β1 integrin with collagens IV and I in vitro and angiogenesis in vivo. The possible therapeutic approach towards tumor neovascularization by targeting the α5β1, αvβ5 and αvβ3 integrins with RGD-bearing disintegrins has been explored in a number of laboratories. Here we discuss structure-function correlations of the novel group of specific (K/R)TS-disintegrins targeting the α1β1 integrin.
Keywords: extracellular matrix, integrin inhibitor, synthetic RGD peptides, obtustatin, viperistatin
Current Pharmaceutical Design
Title: KTS and RTS-Disintegrins: Anti-Angiogenic Viper Venom Peptides Specifically Targeting the α1β 1 Integrin
Volume: 13 Issue: 28
Author(s): Juan J. Calvete, Cezary Marcinkiewicz and Libia Sanz
Affiliation:
Keywords: extracellular matrix, integrin inhibitor, synthetic RGD peptides, obtustatin, viperistatin
Abstract: Integrins α1β1 and α2β1 are highly expressed on the microvascular endothelial cells, and blocking of their adhesive properties significantly reduced the VEGF-driven neovascularization ratio and tumor growth in animal models. Hence, inhibitors of the α1β1 and α2β1 integrins, alone or in combination with antagonists of other integrins involved in angiogenesis (eg. αvβ3, αvβ5, and α6β4), may prove benefitial in the control of tumor neovascularization. Viperidae snakes have developed in their venoms an efficient arsenal of integrin receptor antagonists. KTS- (obtustatin, viperistatin, lebestatin) and RTS- (jerdostatin) disintegrins represent viper venom peptides that specifically block the interaction of the α1β1 integrin with collagens IV and I in vitro and angiogenesis in vivo. The possible therapeutic approach towards tumor neovascularization by targeting the α5β1, αvβ5 and αvβ3 integrins with RGD-bearing disintegrins has been explored in a number of laboratories. Here we discuss structure-function correlations of the novel group of specific (K/R)TS-disintegrins targeting the α1β1 integrin.
Export Options
About this article
Cite this article as:
Calvete J. Juan, Marcinkiewicz Cezary and Sanz Libia, KTS and RTS-Disintegrins: Anti-Angiogenic Viper Venom Peptides Specifically Targeting the α1β 1 Integrin, Current Pharmaceutical Design 2007; 13 (28) . https://dx.doi.org/10.2174/138161207782023766
DOI https://dx.doi.org/10.2174/138161207782023766 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gender Differences in the Clinical Presentation of Heart Disease
Current Pharmaceutical Design Extracellular RNA, a Potential Drug Target for Alleviating Atherosclerosis, Ischemia/Reperfusion Injury and Organ Transplantation
Current Pharmaceutical Biotechnology Functional Imaging Combined with Multi-Detector CT: A Radionuclide Imaging Perspective
Current Medical Imaging Tetracyclic Triterpenoids in Herbal Medicines and their Activities in Diabetes and its Complications
Current Topics in Medicinal Chemistry Reactive Oxygen Species in Myocardial Reperfusion Injury: From Physiopathology to Therapeutic Approaches
Current Pharmaceutical Biotechnology COVID-19 Severity: Lung-Heart Interplay
Current Cardiology Reviews Molecular Chaperone Disorders: Defective Hsp60 in Neurodegeneration
Current Topics in Medicinal Chemistry Hypoxia Inducible Factor-1α, Endothelial Progenitor Cells, Monocytes,Cardiovascular Risk, Wound Healing, Cobalt and Hydralazine:A Unifying Hypothesis
Current Drug Targets Imidazole-based Derivatives as Potential Anti-platelet Inhibitors: DFT and Molecular Docking Study
Letters in Drug Design & Discovery The Role of Mitochondrial Dysfunction in Heart Failure and Potential Therapeutic Targets
Current Pharmaceutical Design Raxofelast, (±)5-(Acetyloxy)-2,3-dihydro-4,6,7-trimethyl-2-benzofuranacetic Acid: A New Antioxidant to Modulate the Inflammatory Response During Ischemia-Reperfusion Injury and Impaired Wound Healing
Mini-Reviews in Medicinal Chemistry HIF Prolyl 4-Hydroxylases and their Potential as Drug Targets
Current Pharmaceutical Design Complications of Anti-Vascular Endothelial Growth Factor Drugs
Current Drug Therapy Hypertension in Type 2 Diabetes Mellitus: Do We Need to Redefine the Role of Sulfonylureas?
Recent Advances in Cardiovascular Drug Discovery (Discontinued) New Uses of Melatonin as a Drug; A Review
Current Medicinal Chemistry Cross-talk between Cellular Stress, Cell Cycle and Anticancer Agents: Mechanistic Aspects
Current Medicinal Chemistry - Anti-Cancer Agents Effects of Hypoxia and Ischemia on MicroRNAs in the Brain
Current Medicinal Chemistry Effects of Nicotine on the Cardiovascular System
Vascular Disease Prevention (Discontinued) Physical Activity and Diabetic Cardiomyopathy: Myocardial Adaptation Depending on Exercise Load
Current Diabetes Reviews A New Approach to the Inflammatory/Autoimmune Diseases
Recent Patents on Anti-Infective Drug Discovery